We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

GeneTAC

Bio-Pharma

Candel Therapeutics Announces Extended Phase 3 Data Presentation at ASTRO 2026

NEEDHAM, Mass., Aug. 3, 2026 Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating...

By cGxPwire Editor
August 4, 2026

Design Therapeutics Reports RESTORE-FA Progress and Advances GeneTAC® Pipeline

CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...

By cGxPwire Editor
August 4, 2026

Recent Posts

01

Bio-Pharma

SciSparc Subsidiary NeuroThera Launches Phase IIb Trial of SCI-110 for Tourette Syndrome
August 6, 2026
02

Bio-Pharma

Leads Biolabs’ Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051
August 6, 2026
03

Bio-Pharma

CellFiber and Tidewave Bio Collaborate on 3D Immunotherapy
August 6, 2026
04

Bio-Pharma

Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
August 6, 2026
05

Bio-Pharma

Insilico Medicine Nominates AI-Designed ISM9077 as Preclinical Candidate for Ocular Diseases
August 6, 2026